TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05330052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agilik
Description: The Agilik is a leg orthosis device supporting the knee joint, and is intended to be worn on one or both the legs. The device is customized for single patient use. It is composed of custom-fabricated polypropylene leg shells (thigh, calf and foot components) with joint supports, actuator, sensors, cabling and a battery waist pack. The Agilik is attached to the patient using straps - two on the thigh and two on the shank. A rotational linkage connects the thigh and calf portions of the device, is placed lateral to the knee joint, and is aligned with the knee center of rotation.
Study: NCT05441098

Intervention type: OTHER
Intervention: Neoadjuvant therapy
Description: Preoperative systemic therapy for breast cancer patients
Study: NCT05848323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-week Cognitive Therapy
Description: A 4-session telehealth Cognitive Therapy intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, self-monitoring thoughts, and core beliefs, b) treatment rationale, b) labeling thoughts as helpful, unhelpful, or neutral, c) using distraction to cope with unhelpful thoughts, d) challenging and changing unhelpful thoughts, e) problem solving barriers to coping with or changing unhelpful thoughts.
Study: NCT06446284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EWM Training
Description: Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Training
Description: Computerized tasks with comparable engagement that do not tap executive working memory processes
Study: NCT06397989

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-use school food
Description: 80 grams of peanut paste-based food containing skim milk powder, cowpea, peanuts, vegetable oil, and multiple micronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard meal
Description: 300ml of porridge made with rice/millet flour
Study: NCT05935423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cell transplantation
Description: 50 million UC MSC will be transplanted 10-15 days after primary PCI
Study: NCT06597968

Intervention type: DEVICE
Intervention: AI Based CAD Software (qXR-Ln)
Description: All x-ray images have already been obtained and will then be run through CAD software for secondary nodule detection
Study: NCT05703464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10mg
Description: Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
Study: NCT06038929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulant
Description: Vagus nerve stimulation involves using a device to stimulate the vagus nerve with electrical impulses. The implanted electrodes transmit electrical impulses travel to areas of the brain to treat conditions (intractable epilepsy, depression) and also send electrical impulses to the stomach.
Study: NCT06729957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Navigation
Description: Care navigation is an intervention that seeks to help patients engage in substance use treatment by increasing motivation and reducing barriers to accessing treatment. The care navigator helps the patient engage in the treatment plan established by the mental health care coordinator.
Study: NCT06731517

Intervention type: PROCEDURE
Intervention: intubation
Description: Double-Lumen Tube Intubation

Intervention type: PROCEDURE
Intervention: intubation
Description: Double-Lumen Tube Intubation

Intervention type: PROCEDURE
Intervention: intubation
Description: Double-Lumen Tube Intubation
Study: NCT06730048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: An appointment will be made to meet with the students in the experimental group in a suitable classroom of the school. After the pre-test data, the students in the experimental group will be shown the preeclampsia case with virtual glasses for about 5-10 minutes. Then the post-test will be applied. A scenario including preeclampsia case and nursing care practices will be created in the virtual reality environment, and 10 experts will be consulted about the scenario before the students are shown it. This application will not have any side effects.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group (placebo)
Description: After the pre-test data, the preeclampsia case will be explained to the students in the control group with the classical lecture method in the Women's Health and Diseases Nursing course and the post-test will be applied.
Study: NCT05020366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Health through Parent Empowerment and the Activation of Routines
Description: Parents will receive a report of their child's current performance and adherence to World Health Organization recommendations in each intervention area. Parents will be coached to build consistent family mealtime routines, in which children are involved in meal preparation, food exploration, and play. They will receive education on appropriate serving sizes for young children and basic information nutrition recommendations. Predictable bedtime routines will be designed to incorporate calming sensory input to improve the transition to bed. Parents will be educated on screen time recommendations and help families brainstorm alternatives to screens, including family-based routines of movement and activity. Finally, parents will be coached to incorporate play into all newly adopted routines, as young children learn though play.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: For the control group, usual care will be enhanced by providing parents with a report of their child's performance and adherence to World Health Organization recommendations in the areas of healthy eating, physical activity, sedentary behavior and sleep. This report will consolidate data based on parent report, written logs, and actigraphy at baseline.
Study: NCT04311281

Intervention type: BIOLOGICAL
Intervention: [F-18]FDDNP-PET
Description: \[F-18\]FDDNP, or 2-(1-{6-\[(2-\[F-18\]fluoroethyl)(methyl)amino\]-2- naphthyl}ethylidene)malononitrile, is a positron emission tomography (PET) radiotracer developed for the in vivo visualization of tau and amyloid-beta (Aβ) deposition in the brain.

Intervention type: BIOLOGICAL
Intervention: [F-18]FDDNP-PET
Description: \[F-18\]FDDNP, or 2-(1-{6-\[(2-\[F-18\]fluoroethyl)(methyl)amino\]-2- naphthyl}ethylidene)malononitrile, is a positron emission tomography (PET) radiotracer developed for the in vivo visualization of tau and amyloid-beta (Aβ) deposition in the brain.
Study: NCT06731751

Intervention type: OTHER
Intervention: Management of spontaneous intracranial haemorrhage
Description: Admission to hospital for spontaneous intracranial haemorrhage management. This includes admission for observation, conservative or interventional (surgical or endovascular) management to both ward-based and critical care settings.
Study: NCT06239571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient Families (R-FAM)
Description: Dyadic, resiliency intervention that aims to reduce depression, anxiety, and posttraumatic stress among parents of babies in the NICU
Study: NCT05423366

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: The ESWT device is product of Elettronica Pagani, Italy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: The ESWT device is product of Elettronica Pagani, Italy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: The ESWT device is product of Elettronica Pagani, Italy.
Study: NCT05867693

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: palmithoylethanolamide/polydatin
Description: Palmitoyl-ethanolamide, a saturated fatty acid amide of palmitic acid commonly found in egg yolk and peanuts, is chemically related to anandamide but exhibit low affinity for cannabinoid receptors, and participate in the control of inflammation and nociception mainly via down-regulation of mast cell activity. In addition, palmitoylethanolamide is able to reduce human colonic permeability both in vitro and in vivo. Interestingly, palmithoylethanolamide may act as mast cell modulator as a possible agonist for cannabinoid 2-like receptors; and as agonist for PPAR-α, transient receptor potential vanilloid type 1 (TRPV1), and 'orphan' G protein-coupled receptor 55.~For these reasons, palmithoylethanolamide has emerged as potential regulators of nociception. Polydatin, a resveratrol glucoside, is a common dietary component derived from grapes which may act synergistically with palmithoylethanolamide in reducing mast cell activation and local oxidative stress.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After the screening phase, eligible patients will be randomly assigned to equivalent placebo
Study: NCT04712513

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic cardiac CT perfusion imaging
Description: Multiple images of the heart are acquired with a clinical CT scanner after an intravenous bolus injection of contrast solution. The images are then analyzed to provide fractional flow reserve and myocardial perfusion values.
Study: NCT06291623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin
Description: used as intracanal medication for one week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin
Description: used as intracanal medication for one week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin
Description: used as intracanal medication for one week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin
Description: used as intracanal medication for one week
Study: NCT06428032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand-Arm Bimanual Intensive Therapy Including Lower Extremities
Description: Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand-Arm Bimanual Intensive Therapy Including Lower Extremities
Description: Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
Study: NCT05691972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Contour
Description: a sterile, biodegradable, transparent gel of nonanimal cross-linked HA (20 mg/mL) with the addition of lidocaine hydrochloride (3 mg/mL)
Study: NCT02800824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Uceris
Study: NCT05752045

Intervention type: DEVICE
Group type: OTHER
Intervention: Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device
Description: Double ophthalmological imaging capture of eye fundus with different fundus camera to screen patient for various eye diseases.
Study: NCT05889845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candin, Intradermal Solution
Description: Injection at the base of the selected wart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection at the base of the selected wart
Study: NCT05851664

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intubation by direct laryngoscopy
Description: intubation using a direct laryngoscopy type macintosh

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation by videolaryngoscopy
Description: Intubation using a videolaryngoscope type McGrath
Study: NCT05892549

Intervention type: DEVICE
Intervention: COVOICE application use - initial
Description: Recording (only once) of sound related to respiratory movements, coughing and voice using a mobile phone application

Intervention type: DEVICE
Intervention: COVOICE application use - follow-up
Description: Daily recording of sound related to respiratory movements, coughing and voice using a mobile phone application. Duration: up to 30 days

Intervention type: DEVICE
Intervention: COVOICE application use - follow-up
Description: Daily recording of sound related to respiratory movements, coughing and voice using a mobile phone application. Duration: up to 30 days
Study: NCT05055856

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: urine sample
Description: Each participant will give a urine sample for diagnose of asymptomatic bacteriuria

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: urine sample
Description: Each participant will give a urine sample for diagnose of asymptomatic bacteriuria

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood and urine sample
Description: Each participant will give a urine and blood sample for diagnose of SIADH

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Blood and urine sample
Description: Each participant will give a urine and blood sample for diagnose of SIADH
Study: NCT05838911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group chest physiotherapy program combined with neuromuscular electrical stimulation (NMES)
Description: The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group Chest physical therapy
Description: The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks
Study: NCT05074771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC intellicare
Description: ARC is a system that allows home motor and respiratory rehabilitation. The system includes 5 inertial measurement units for limbs and neck, a tablet with a dedicated app installed, to acquire and monitor the exercises performed by the patient in his/her daily rehab activity. Sensors and tablet can be charged on the base station. ARC allows the therapist to tailor the individual rehab project, with the support of a monitoring dashboard. The artificial intelligence engine analyses data coming from sensors positioned on the limbs, providing real-time feedback to the patient on the correct number of repetitions performed for each exercise. ARC allows therapists to create new exercises and/or select exercises from the ARC library to customize treatment (including tutorials and tips) based on condition-specific validated protocols and best practice. Patients can safely perform home rehabilitation sessions by wearing sensors and following video tutorials and tips from the ARC library.
Study: NCT04843982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride
Description: After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.
Study: NCT04205136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: If tolerated and serum potassium \<5.0 meq/L, the dose will be increased to 50 mg (2 pills) after 4 weeks. If serum potassium is \>5.0 but less than 5.5 or creatinine \>4.0 mg/dL, the dose will be adjusted to 25 mg every other day; if potassium levels ≥5.5 in a non-hemolyzed blood sample, the medication will be discontinued.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to the placebo group will take one pill for the first 4 weeks and a second pill for the remaining 8 weeks.
Study: NCT06402214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lombard test
Description: In this study a single-subject enrolment session will be set up, with the presence of a dedicated physician for informed consent, the performance of a tonal audiometric examination and a clinical practice phoniatric examination for all enrolled subjects, the collection of voice recordings both before and during the Lombard Test (LT) and the administration of the rating scales both before and after the LT performance. For each subject, voice recordings will be made of the vowel /a/ sustained for at least four seconds with a comfortable tone and volume and of the speech obtained from the reading aloud and volume of normal conversation of a phonetically balanced text (The Desert) lasting about 1 minute, first in a silent condition and then in the presence of noise. Specifically, for the LT, each subject will be exposed to a free-fieldwhite noise of speech(SWN) administered through headphones. The intensity of the noise will be 70 dB SPL. Voice recordings will be made in a quiet room.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lombard test
Description: In this study a single-subject enrolment session will be set up, with the presence of a dedicated physician for informed consent, the performance of a tonal audiometric examination and a clinical practice phoniatric examination for all enrolled subjects, the collection of voice recordings both before and during the Lombard Test (LT) and the administration of the rating scales both before and after the LT performance. For each subject, voice recordings will be made of the vowel /a/ sustained for at least four seconds with a comfortable tone and volume and of the speech obtained from the reading aloud and volume of normal conversation of a phonetically balanced text (The Desert) lasting about 1 minute, first in a silent condition and then in the presence of noise. Specifically, for the LT, each subject will be exposed to a free-fieldwhite noise of speech(SWN) administered through headphones. The intensity of the noise will be 70 dB SPL. Voice recordings will be made in a quiet room.
Study: NCT05153785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravenous perioperative Lidocain for pain Control and improvement of postoperative recovery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study: NCT06345326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Greater occipital nerve block
Description: The nerve block will be done by ultrasound guidiance at the C2 level with a 22 gauge 5 cm needle inplane direction. The pulse radiofrequency will be done as defined with a radiofrequency cannula- 5 cm with an active tip of 2mm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Greater occipital nerve block
Description: The nerve block will be done by ultrasound guidiance at the C2 level with a 22 gauge 5 cm needle inplane direction. The pulse radiofrequency will be done as defined with a radiofrequency cannula- 5 cm with an active tip of 2mm.
Study: NCT05652790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced Rehabilitation Programme
Description: The ERP would be offered at least two sessions, each lasting 60-120 minutes per week, delivered in the Manchester Institute of Health and Performance. Interventions may include a combination of the following depending on the individual patient needs.~Manual Therapy Hydrotherapy Exercise Strength and Conditioning Programmes Gait re-education Pilates/ Yoga Cognitive and Vocational Rehabilitation Occupation Therapy Interventions eg. Anxiety Management, Pacing, Cognitive Behavioural Therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Care
Description: Standard care received at usual NHS facility
Study: NCT04784455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nomacopan (rVA576)
Description: The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within a year of HSCT
Study: NCT05367206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 260mg/m2 q3w \*2 circles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5-6 q3w \* 2 circles
Study: NCT05101915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP301
Description: Inhaled IMP delivered via nebulisation
Study: NCT05010785

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement and alveolar ridge splitting with GBR and i-PRF
Description: Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with i-PRF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant placement and alveolar ridge splitting with GBR
Description: Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
Study: NCT05832229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor) or matching placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Patients meeting all eligibility criteria will be assigned to a randomization arm prior to initiation of a 4-week lead-in phase of the study. All participants will undergo a 4-week, open-label active run-in phase to evaluate initial safety and adherence to rosuvastatin. During this active run-phase, all participants will receive target dose rosuvastatin-- 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor). After the active run-in phase, all participants will continue with their pre-assigned randomization (1:1) treatment of rosuvastatin 20 mg daily (10 mg daily for participants of East-Asian ancestry or on a protease inhibitor) or matching placebo.